Imatinib (Gleevec®) as a paradigm of targeted cancer therapies

Brian Druker

doi:10.2302/kjm.59.1

Imatinib (Gleevec®) as a paradigm of targeted cancer therapies

Brian Druker

Knight Cancer Institute

Research output: Contribution to journal › Article

5 Scopus citations

Original language	English (US)
Pages (from-to)	1-3
Number of pages	3
Journal	Keio Journal of Medicine
Volume	59
Issue number	1
DOIs	https://doi.org/10.2302/kjm.59.1
State	Published - Mar 1 2010

Keywords

CML
Imanitib
Leukemia
Molecularly targeted therapy

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.2302/kjm.59.1

Cite this

@article{4164111c9bd842cc94e2964f99cb9caa,

title = "Imatinib (Gleevec{\textregistered}) as a paradigm of targeted cancer therapies",

keywords = "CML, Imanitib, Leukemia, Molecularly targeted therapy",

author = "Brian Druker",

year = "2010",

month = mar,

day = "1",

doi = "10.2302/kjm.59.1",

language = "English (US)",

volume = "59",

pages = "1--3",

journal = "Keio Journal of Medicine",

issn = "0022-9717",

publisher = "Keio University School of Medicine",

number = "1",

}

TY - JOUR

T1 - Imatinib (Gleevec®) as a paradigm of targeted cancer therapies

AU - Druker, Brian

PY - 2010/3/1

Y1 - 2010/3/1

KW - CML

KW - Imanitib

KW - Leukemia

KW - Molecularly targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=77954302007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954302007&partnerID=8YFLogxK

U2 - 10.2302/kjm.59.1

DO - 10.2302/kjm.59.1

M3 - Article

C2 - 20375651

AN - SCOPUS:77954302007

VL - 59

SP - 1

EP - 3

JO - Keio Journal of Medicine

JF - Keio Journal of Medicine

SN - 0022-9717

IS - 1

ER -